

## FORTHCOMING PAPERS IN THE JOURNAL OF STEROID BIOCHEMISTRY

*Vol. 36, No. 3*

The next issue of *The Journal of Steroid Biochemistry* will be a Special Issue consisting of papers from the *Proceedings of the Toremifene Satellite Symposium* held at the *UICC World Cancer Congress*, Budapest, Hungary, 1986

- M. BAUM: The role of endocrine therapy in primary breast cancer
- L. KANGAS: Review of the pharmacological properties of toremifene
- N. H. SIMBERG, J. T. MURAI and P. K. SIITERI: *In vitro* and *in vivo* binding of toremifene and its metabolites in the rat uterus
- E. DI SALLE, T. ZACCHEO and G. ORNATI: Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat
- A. WARRI and L. KANGAS: Effect of toremifene on the activity of NK-cells in NZB/NZW mice
- H. SIPILA, L. KANGAS, L. VUORILEHTO, A. KALAPUDAS, M. ELORANTA, M. SODERVALL, R. TOIVOLA and M. ANTTILA: Metabolism of toremifene in the rat
- S. KIVINEN and J. MAENPAA: Effect of toremifene on clinical chemistry, hematology and hormone levels at different doses in healthy postmenopausal volunteers: phase II study
- J. MAENPAA, K.-O. SODERSTROM, M. GRONROOS, E. TAINA, A. HAJBA and L. KANGAS: Effect of toremifene on estrogen primed vaginal mucosa in postmenopausal women
- I. HINDY, E. JUHOS, J. SZANTO and I. SZAMEL: Effect of toremifene in breast cancer patients. Preliminary communication
- S. PYRHONEN, R. VALAVAARA, M. HEIKKINEN, P. RISSANEN, G. BLANCO, E. NORDMAN, L. R. HOLSTI and A. HAJBA: Treatment of advanced breast cancer with 20 mg toremifene, a phase II study. Preliminary communication
- R. VALAVAARA, S. PYRHONEN, M. HEIKKINEN, P. RISSANEN, G. BLANCO, E. NORDMAN, P. TASKINEN, L. R. HOLSTI and A. HAJBA: Safety and efficacy of toremifene in breast cancer patients. A phase II study
- S. GUNDERSEN: Toremifene, a new antiestrogenic compound in the treatment of metastatic mammary cancer. A phase II study
- H. MODIG, S. BORGSTROM, I. NILSSON and G. WESTMAN: Phase II clinical study of toremifene in patients with metastatic breast cancer. Preliminary communication
- H. MODIG, S. BORGSTROM, I. NILSSON and G. WESTMAN: Phase II clinical study of high-dose toremifene in patients with advanced breast cancer
- S. R. EBBS, J. ROBERTS and M. BAUM: Response to toremifene (Fc-1157a) therapy in tamoxifen failed patients with breast cancer. Preliminary communication
- G. HORVATH, C. TROPE and H.-E. ALMBO: A phase II study of toremifene in carcinoma corporis uteri. Preliminary communication
- I. SZAMEL, B. VINCZE, I. HINDY, S. KERPEL-FRONIUS, S. ECKHARDT, J. MAENPAA, M. GRONROOS, L. KANGAS, H. SUNDQUIST and A. HAJBA: Hormonal effects of toremifene in breast cancer patients
- M. ANTTILA, R. VALAVAARA, S. KIVINEN and J. MAENPAA: Pharmacokinetics of toremifene
- L. KANGAS and M. GRONROOS: Antitumor effects of combination toremifene and medroxyprogesterone acetate (MPA) *in vitro* and *in vivo*
- L. KANGAS, K. CANTELL and H. SCHELLEKENS: Additive and synergistic antitumor effects with toremifene and interferons